Multiple Myeloma
From the Journals
Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant
But only if caregivers are equipped for outpatient care.
Conference Coverage
Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma
From the Journals
Extended virus shedding after COVID-19 in some patients with cancer
Some patients, including stem cell transplant and CAR T recipients, may require extended periods of isolation.
Conference Coverage
Five-minute SC injection of daratumumab in RRMM
“The appeal of subcutaneous daratumumab is the 5 minutes it needs for administering, cutting down considerable on ‘chair/clinic’ time.”
Conference Coverage
Durable responses with anti-BCMA CAR T-cell for multiple myeloma
Seventy-two percent of patients with relapsed/refractory multiple myeloma had ongoing responses at the time of data cutoff in the CARTITUDE-1...
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
From the Journals
Circulating miRNA could be a potential biomarker for early diagnosis of MM
A meta-analysis found that using circulating microRNAs had high sensitivity and specificity in the early diagnosis of multiple myeloma.
Conference Coverage
Home care for bortezomib safe and reduces hospital visits in myeloma patients
From the Journals
Socioeconomic factors affect survival of multiple myeloma patients
From the Journals
Older adults with multiple myeloma face heavy burden of care
From the Journals
Initial response to novel agents preps MM patients for favorable transplant outcomes
Triplet induction outperformed doublet in early outcomes, but later outcome differences were not statistically significant.